Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8490)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 15, 2016 (publication date) through Jul 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chatterjee S, Ghosal S, Chatterjee S. Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. World J Diabetes 2016; 7(18): 441-448 [PMID: 27795818 DOI: 10.4239/wjd.v7.i18.441] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v7/i18/441.htm |
| Number | Citing Articles |
| 1 |
Miles Congreve, John A. Christopher, Chris de Graaf. Burger's Medicinal Chemistry and Drug Discovery. 2021; : 1 doi: 10.1002/0471266949.bmc269
|
| 2 |
Mark F McCarty, Aaron Lerner. Perspective: Prospects for Nutraceutical Support of Intestinal Barrier Function. Advances in Nutrition 2021; 12(2): 316 doi: 10.1093/advances/nmaa139
|
| 3 |
Yajie Dong, Qingguo Lv, Sheyu Li, Yuan Wu, Ling Li, Juan Li, Fang Zhang, Xin Sun, Nanwei Tong. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2017; 41(3): 284 doi: 10.1016/j.clinre.2016.11.009
|
| 4 |
Carol H. Wysham, Carlos Campos, Davida Kruger. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications. Clinical Diabetes 2018; 36(2): 149 doi: 10.2337/cd17-0064
|
| 5 |
Hidetaka Hamasaki. Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?. World Journal of Diabetes 2018; 9(8): 138-140 doi: 10.4239/wjd.v9.i8.138
|
| 6 |
Vimala Ananthy, Raman Palanyswamy Priyadharsini, Umamaheswari Subramanian. Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive Review. SBV Journal of Basic, Clinical and Applied Health Science 2021; 4(2): 39 doi: 10.5005/jp-journals-10082-03111
|
| 7 |
Rajesh Rajput, Sujoy Ghosh, Samar Banerjee, Beena Bansal, Manoj Chawla, AbhayI Ahluwalia, Tejal Lathia, AshokK Das. First-in-class oral semaglutide: Overcoming barriers of incretinisation in the Indian context. Indian Journal of Endocrinology and Metabolism 2022; 26(5): 417 doi: 10.4103/ijem.ijem_217_22
|
| 8 |
Andrea Bortolato, Jonathan S. Mason. Contemporary Accounts in Drug Discovery and Development. 2022; : 179 doi: 10.1002/9781119627784.ch9
|
| 9 |
Ting Xiang, Siliang Zhang, Qinge Li, Ling Li, Hua Liu, Chen Chen, Gangyi Yang, Mengliu Yang. GPHB5 Is a Biomarker in Women With Metabolic Syndrome: Results From Cross-Sectional and Intervention Studies. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.893142
|
| 10 |
Raphael Alhadeff, Arieh Warshel. A free‐energy landscape for the glucagon‐like peptide 1 receptor GLP1R. Proteins: Structure, Function, and Bioinformatics 2020; 88(1): 127 doi: 10.1002/prot.25777
|
| 11 |
Sam N. Scott, Charlotte Hayes, Thomas Zeuger, Andrew P. Davies, Rob C. Andrews, Matthew Cocks. Clinical Considerations and Practical Advice for People Living With Type 2 Diabetes Who Undertake Regular Exercise or Aim to Exercise Competitively. Diabetes Spectrum 2023; 36(2): 114 doi: 10.2337/dsi22-0015
|
| 12 |
Ming Wang, Gwangho Yoon, Juhyun Song, Jihoon Jo. Exendin-4 improves long-term potentiation and neuronal dendritic growth in vivo and in vitro obesity condition. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-87809-4
|
| 13 |
Haaglim Cho, JungIn Um, Ji-Hyung Lee, Woong-Hee Kim, Wan Seok Kang, So Hun Kim, Hyung-Ho Ha, Yong-Chul Kim, Young-Keun Ahn, Da-Woon Jung, Darren R. Williams. ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes. Scientific Reports 2017; 7(1) doi: 10.1038/srep44186
|
| 14 |
Olusola F. Onoviran, Dongming Li, Sarah Toombs Smith, Mukaila A. Raji. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Therapeutic Advances in Chronic Disease 2019; 10: 204062231986269 doi: 10.1177/2040622319862691
|
| 15 |
Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Manash Pratim Baruah, Mangesh Tiwaskar, Sambit Das, Sudip Chatterjee, Banshi Saboo, Ganapathi Bantwal, Saptarshi Bhattacharya, Gagan Priya, Manoj Chawla, Kiraninder Brar, Syed Abbas Raza, Azizul Hasan Aamir, Dina Shrestha, Noel Somasundaram, Prasad Katulanda, Faria Afsana, Shahjada Selim, Mohammad Wali Naseri, Ali Latheef, Manilka Sumanatilleke. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Therapy 2019; 10(5): 1645 doi: 10.1007/s13300-019-0669-4
|
| 16 |
Holly J. Kramer, Shivam Joshi. Nutritional Management of Renal Disease. 2022; : 763 doi: 10.1016/B978-0-12-818540-7.00028-8
|
| 17 |
Ali Jazayeri, Mathieu Rappas, Alastair J. H. Brown, James Kean, James C. Errey, Nathan J. Robertson, Cédric Fiez-Vandal, Stephen P. Andrews, Miles Congreve, Andrea Bortolato, Jonathan S. Mason, Asma H. Baig, Iryna Teobald, Andrew S. Doré, Malcolm Weir, Robert M. Cooke, Fiona H. Marshall. Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature 2017; 546(7657): 254 doi: 10.1038/nature22800
|
| 18 |
Elizabeth G. Mietlicki-Baase, Lauren E. McGrath, Kieran Koch-Laskowski, Joanna Krawczyk, Tram Pham, Rinzin Lhamo, David J. Reiner, Matthew R. Hayes. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance. Physiology & Behavior 2017; 173: 9 doi: 10.1016/j.physbeh.2017.01.038
|
| 19 |
Nabilah Ibnat, Rahela Zaman, Mohammad Borhan Uddin, Ezharul Chowdhury, Chooi Yeng Lee. Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in rats. World Journal of Diabetes 2022; 13(8): 613-621 doi: 10.4239/wjd.v13.i8.613
Abstract(490) |
Core Tip(356) |
Full Article(HTML)(1747)
|
Full Article (PDF)-1178K(123)
|
Full Article (Word)-665K(53)
|
Audio-10192K(1)
|
Peer-Review Report-211K(48)
|
Answering Reviewers-75K(47)
|
Times Cited (0)
|
Total Visits (5292)
|
Open
|
| 20 |
Adriana M. Zago, Fabiano B. Carvalho, Francine L. Rahmeier, Marta Santin, Giuliano R. Guimarães, Jessié M. Gutierres, Marilda da C. Fernandes. Exendin-4 Prevents Memory Loss and Neuronal Death in Rats with Sporadic Alzheimer-Like Disease. Molecular Neurobiology 2024; 61(5): 2631 doi: 10.1007/s12035-023-03698-w
|
| 21 |
Lei Zhang, Shi-Tao Zhang, Yan-Chun Yin, Shu Xing, Wan-Nan Li, Xue-Qi Fu. Hypoglycemic effect and mechanism of isoquercitrin as an inhibitor of dipeptidyl peptidase-4 in type 2 diabetic mice. RSC Advances 2018; 8(27): 14967 doi: 10.1039/C8RA00675J
|